supplied by www.ccc.ac.at

2 Einträge

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Autoren Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SK, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M
Erscheinungsdaten The Lancet. Oncology. 2016 Feb 10. pii: S1470-2045(15)00551-3. doi: 10.1016/S1470-2045(15)00551-3
Publikations ID PMID: 26874901
 


Expert Discussion: ASCO 2022.
Autoren Balic M, Wimmer K, Suppan C, Silovski T, Brunner C
Erscheinungsdaten Breast care (Basel, Switzerland). 2022 Jul 8. doi: 10.1159/000525966. pii: brc-0017-0430. pmc: PMC9453657
Publikations ID PMID: 36156916